Just weeks after signing a $900 million pact with Incyte for its early-stage PD-1 checkpoint, MacroGenics $MGNX is back with a new deal covering the development of bispecifics for a variety of diseases for Roche. Roche $RHHBY, which just bought out Ignyta for $1.7 billion, is paying a modest $10 million upfront for the pact and committing to up to $370 million in milestones.
The collaboration brings together the biotech’s DART platform and Roche’s CrossMAb and DutaFab technologies.
“MacroGenics and Roche are both leaders in the field of bispecifics and have each advanced numerous molecules into clinical testing. By combining our two companies’ respective scientific talent, technology platforms and experience, we hope to generate a compelling product candidate to address unmet patient needs,” said MacroGenics CEO Scott Koenig.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.Free Subscription